A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult and Adolescent Patients
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs SAR 439794 (Primary) ; Glycopyranosyl lipid adjuvant
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors Sanofi
- 24 Jul 2019 Planned End Date changed from 27 Apr 2020 to 1 Mar 2020.
- 09 May 2019 Planned End Date changed from 30 Mar 2020 to 27 Apr 2020.
- 11 Mar 2019 Planned End Date changed from 1 Mar 2020 to 30 Mar 2020.